酵素的に分解され,非酸化されたLDLは,人間の血管の滑らかな筋肉細胞の活性化,泡細胞の変容,および増殖を誘発する
M Klouche1, S Rose-John, W Schmiedt
1Institute of Medical Microbiology, University of Mainz, Germany. klouche@mail.uni-mainz.de
Circulation
|April 19, 2000
まとめ
酵素的に改変されたLDL (E-LDL) は,血管の滑らかな筋肉細胞 (SMC) の増殖を誘発し,その遺伝子発現を変化させ,早期の動脈硬化病変の発達に貢献します.
科学分野:
- 心血管生物学 心血管生物学
- 動脈硬化症の研究研究
- 細胞および分子医学は,細胞および分子医学である.
背景:
- LDLの酵素的,非酸化的改変により,アテロゲン形 (E-LDL) が形成されます.
- E-LDLはコンプリメントとマクロファージを活性化し,早期アテロスクレロティック病変に現れます.
研究 の 目的:
- 人間の血管の滑らかな筋肉細胞 (SMC) に対するE-LDLのアテロゲン効果を調査する.
主な方法:
- SMCにおける評価されたE-LDL蓄積.
- ケモカインと炎症タンパク質の遺伝子発現を測定した.
- gp130とIL-6受容体 (IL-6R) ファミリーシグナリングを分析した.
- 調査されたE-LDL誘発SMCの拡散メカニズム.
主要な成果:
- SMCに蓄積されたE-LDLは,選択的に単細胞化学作用タンパク質-1を誘導する.
- E-LDLはgp130の発現とIL-6の分泌を刺激した.
- E-LDLは,オトクリン成長因子回路とIL-6/sIL-6Rトランスシグナルを通じたSMCの増殖を促進した.
- マクロファージ由来IL-6と溶性IL-6受容体 (sIL-6R) は,SMCの増殖を強めた.
結論:
- E-LDLは,動脈硬化病変の進化の特徴であるSMCの変化を誘発する.
- E-LDLは,早期動脈硬化で観察される細胞の変化に寄与する.
関連する概念動画
Inflammation
Overview
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


